Hypertension (Presumed)
Hypertension (Presumed)
Clinic note 2026-05-06: "she is not taking nifedipine." The antihypertensive regimen is now losartan monotherapy only (assuming losartan adherence, which is also unconfirmed). This further increases the need to document blood pressure readings. See Nifedipine for full history.
Clinical Summary
Hypertension is PRESUMED based on antihypertensive medications on the 2026-05-04 prescription. The active prescribed antihypertensive:
1. Losartan (Lo) — 50 mg once daily (ARB) — active (adherence unconfirmed)
2. ~~Nifedipine~~ — NOT BEING TAKEN (confirmed 2026-05-06 clinic note)
No blood pressure readings have been documented in any ingested raw source (no clinic notes, no lab reports, no home monitoring records).
- No BP readings documented — cannot confirm hypertension diagnosis or assess treatment efficacy
- Date of diagnosis unknown
- Target BP unknown
- Home BP monitoring status unknown
- Baseline pre-treatment BP unknown
- Nifedipine not being taken — if HTN is confirmed, losartan monotherapy alone may be insufficient
Indication for Antihypertensive Therapy
Losartan and nifedipine may be prescribed for:
- Hypertension (most likely)
- Diabetic nephropathy protection — ARBs (losartan) are first-line for renoprotection in diabetes, even in normotensive patients with microalbuminuria
- Cardiovascular risk reduction — diabetes itself is an indication for ARB therapy
Given Ishamma's Diabetes Mellitus diagnosis, losartan may be prescribed for renoprotection rather than (or in addition to) BP control.
Medications
Losartan (Cozaar / Lo) — ARB
- Dose: 50 mg once daily (afternoon, 0-1-0)
- Indication: Hypertension / diabetic nephropathy protection
- Mechanism: Blocks angiotensin II AT1 receptors → vasodilation, reduced proteinuria, renoprotection
- Advantages in diabetes: Slows diabetic nephropathy progression, reduces cardiovascular events
- Monitoring needs:
- Blood pressure (NOT YET DOCUMENTED)
- Serum potassium (hyperkalemia risk) — currently normal (K+ 4.0 mmol/L May 4)
- Renal function (creatinine, eGFR) — currently normal (Cr 0.7–0.9 mg/dL)
- Microalbuminuria / UACR (assess renoprotection efficacy) — NOT YET DOCUMENTED
Nifedipine — Calcium Channel Blocker (CCB) — NOT BEING TAKEN
- Prescribed dose: 30 mg twice daily (1-0-1) — on 2026-05-04 Rx
- Status: Patient confirmed not taking as of 2026-05-06
- ~~Drug interaction with posaconazole (CYP3A4)~~ — RESOLVED: interaction moot since medication not being taken
- Action needed: Discuss with prescriber — resume, switch, or formally discontinue. If HTN is confirmed, losartan monotherapy alone may not achieve target BP in an 81-year-old diabetic.
Antihypertensive Regimen — Current Effective Status (2026-05-06)
| Medication | Prescribed | Being Taken | Notes |
|---|---|---|---|
| Losartan 50 mg OD | Yes | Unknown | Adherence unconfirmed |
| Nifedipine 30 mg b.i.d. | Yes (Rx dated 2026-05-04) | NO | Confirmed not taking (clinic note 2026-05-06) |
If hypertension is confirmed, ARB + CCB is a preferred combination for hypertensive diabetics. The current de facto regimen (losartan monotherapy) may be insufficient for BP control. Prescriber notification is warranted.
Monitoring Gaps
| Parameter | Status | Action Needed |
|---|---|---|
| Blood pressure readings | NONE documented | Obtain home BP log or clinic BP records — urgent given non-adherence |
| Microalbuminuria (UACR) | NOT documented | Check urinalysis for diabetic nephropathy screening |
| Peripheral edema assessment | NOT applicable | Nifedipine not being taken; no CCB on board |
| Medication adherence | Nifedipine: confirmed NOT taken (2026-05-06) | Losartan adherence also unconfirmed; notify prescriber |
[!info] Renoprotection vs. Hypertension
If BP is actually normal (normotensive), losartan may still be indicated for diabetic nephropathy protection. ARBs reduce proteinuria and slow renal decline in diabetes even without hypertension.Without BP data, the primary indication cannot be determined.
Drug Interactions — CYP3A4
[!info] Posaconazole-Nifedipine Interaction — RESOLVED (2026-05-06)
This interaction was flagged on 2026-05-04 when nifedipine was discovered on the prescription. As of 2026-05-06, patient confirmed NOT taking nifedipine. The CYP3A4 interaction with posaconazole is no longer clinically relevant.If nifedipine is restarted in the future, this interaction must be re-evaluated given ongoing posaconazole use.
Related Conditions
- Diabetes Mellitus — ARB indicated for renoprotection; CCB has no adverse metabolic effects
- Aml — Posaconazole (antifungal prophylaxis) interacts with nifedipine
Related Labs
- Potassium — Monitor for losartan-induced hyperkalemia (currently normal, 4.0 mmol/L)
- Creatinine — Monitor renal function (currently normal, 0.7–0.9 mg/dL)
- Microalbuminuria / UACR — Should be checked (not yet documented)
Condition page created during ingest of 2026-05-04 prescription. Hypertension diagnosis is PRESUMED based on medications. No BP readings documented. Updated 2026-05-06: nifedipine confirmed not being taken — antihypertensive regimen is now losartan monotherapy only.